157 related articles for article (PubMed ID: 9480401)
1. [Economic analysis of secondary prevention of coronary heart disease with simvastatin (Zocor) in Germany].
Obermann K; Mattias Graf ; Schulenburg JM; Mautner GC
Med Klin (Munich); 1997 Nov; 92(11):686-94. PubMed ID: 9480401
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
[TBL] [Abstract][Full Text] [Related]
4. [Cost-benefit analysis of an evidence-based secondary prevention of coronary heart diseases by statins. An analysis for Germany from a social security perspective].
Klever-Deichert G; Hinzpeter B; Wendland G; Lauterbach K
Med Klin (Munich); 2000 Jun; 95(6):305-13. PubMed ID: 10935414
[TBL] [Abstract][Full Text] [Related]
5. Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease.
Attanasio E; Russo P; Allen SE
Clin Ther; 2001 Feb; 23(2):276-83; discussion 274-5. PubMed ID: 11293560
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.
Pharoah PD; Hollingworth W
BMJ; 1996 Jun; 312(7044):1443-8. PubMed ID: 8664620
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin after orthotopic heart transplantation. Costs and consequences.
Krobot KJ; Wenke K; Reichart B
Pharmacoeconomics; 1999 Mar; 15(3):279-89. PubMed ID: 10537435
[TBL] [Abstract][Full Text] [Related]
9. [Effect of medicamentous cholesterol control on resources utilization in public health--significance of the Scandinavian Simvastatin Survival Study (4-S Study) for cost control in Swiss health management conditions].
Szucs TD; Lüscher TF; Gutzwiller F
Schweiz Med Wochenschr; 1997 Nov; 127(44):1819-23. PubMed ID: 9446200
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of statin medications.
Kaplan RM; Golomb BA
Am Psychol; 2001 Apr; 56(4):366-7. PubMed ID: 11330239
[No Abstract] [Full Text] [Related]
11. [Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
Klose G
Fortschr Med; 1996 Jun; 114(17):231-2. PubMed ID: 8767302
[No Abstract] [Full Text] [Related]
12. Health and economic issues in the prevention of coronary artery disease.
Hogan T
Am J Cardiol; 1995 Jul; 76(2):140A-142A. PubMed ID: 7604790
[No Abstract] [Full Text] [Related]
13. LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor) in Thai hypercholesterolemic subjects -- a randomized crossover study, the first report from Thailand.
Wiwanitkit V; Wangsaturaka D; Tangphao O
BMC Clin Pharmacol; 2002; 2():1. PubMed ID: 11835697
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.
Rivière M; Wang S; Leclerc C; Fitzsimon C; Tretiak R
CMAJ; 1997 Apr; 156(7):991-7. PubMed ID: 9099167
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic outcomes in patients switched to simvastatin in a community-based family medicine practice.
Willey VJ; Reinhold JA; Willey KH; Kelly BL; Cziraky MJ
Int J Clin Pract; 2010 Aug; 64(9):1235-8. PubMed ID: 20653799
[TBL] [Abstract][Full Text] [Related]
16. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
Koren MJ; Smith DG; Hunninghake DB; Davidson MH; McKenney JM; Weiss SR; Schrott HG; Henley RW; Tresh P; McLain RW; Bakker-Arkema RG; Black DM
Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S).
Jönsson B; Johannesson M; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
Eur Heart J; 1996 Jul; 17(7):1001-7. PubMed ID: 8809516
[TBL] [Abstract][Full Text] [Related]
19. Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management.
Pedersen TR
Am J Cardiol; 2001 Mar; 87(5A):8B-12B. PubMed ID: 11256850
[TBL] [Abstract][Full Text] [Related]
20. [Simvastatin 40 mg as secondary prophylaxis: Effective, tolerable and cost-efficient!].
Hernborg A; Hjemdahl P; Håkansson J
Lakartidningen; 2006 Mar 15-21; 103(11):858, 861; discussion 861-2. PubMed ID: 16613120
[No Abstract] [Full Text] [Related]
[Next] [New Search]
